Concerns that US tariffs on Australian pharmaceuticals could deliver a major blow to the economy appear overstated, according to the International Monetary Fund’s latest assessment of Australia’s outlook, which instead points to rising and mostly unavoidable health spending as the far more significant long-term policy challenge.
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News

